P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Abstract

CAFs increases tumor growth while knockdown of CNTFR in lung tumor cells decreases overall growth. With the use of advanced protein engineering technology, we generated a high-affinity CNTFR decoy that inhibits CLCF1-CNTFR signaling and are currently testing this novel reagent to elucidate the mechanism by which CNTFR activation alters intercellular signaling to increase tumor cell growth. Through in vivo studies with cell lines and PDXs, we are also exploring the efficacy of this CNTFR decoy as a form of lung cancer therapy. Conclusion:In sum, these data indicate that CLCF1-CNTFR signaling is important for NSCLC tumor growth and is a viable therapeutic target.

The care of older cancer patients in the United Kingdom

“…In this cohort, a series of blood tests have been shown to predict the frailty and subsequent mortality [32]. The pilot work then showed key differences in these blood tests in patients with lung cancer from the Newcastle 85+ cohort and showed that they can predict mortality [33]. In addition, sarcopenia is a key element of frailty, and this was investigated in Newcastle by assessing grip strength which when adjusted for age and gender has a prognostic value in cancer patients awaiting clinical trials [34].…”

Associação entre cistatina C, fragilidade e desfechos clínicos em idosos com câncer

“…No carcinoma pulmonar de células não pequenas (NSCLC), biomarcadores, incluindo comprimento de telômero, adiponectina, PCR de alta sensibilidade, proteína ligadora de IGF-1, Fator de Crescimento Transformador Beta (TGF-B), alfa-1 glicoproteína ácida e ligante Tirosino-quinase 3 Fms-relacionado (FLT3) foram biomarcadores circulantes de fragilidade que se correlacionaram com um mau prognóstico em pacientes com NSCLC. 34 A Interleucina-6 I é outro marcador promissor na previsão de fragilidade.…”